46 related articles for article (PubMed ID: 7527733)
21. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer.
Dexeus F; Logothetis CJ; Samuels ML; Hossan E; von Eschenbach AC
Cancer Treat Rep; 1985; 69(7-8):885-6. PubMed ID: 4016795
[TBL] [Abstract][Full Text] [Related]
22. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
Tannock IF
J Clin Oncol; 1985 Jul; 3(7):1013-21. PubMed ID: 3894584
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of cyclophosphamide, adriamycin, and cis-platinum (CAP) in patients with disseminated prostatic carcinoma. A phase II study.
Drelichman A; Oldford J; Al-Sarraf M
Am J Clin Oncol; 1985 Jun; 8(3):255-9. PubMed ID: 3840326
[TBL] [Abstract][Full Text] [Related]
24. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
Kasimis BS; Miller JB; Kaneshiro CA; Forbes KA; Moran EM; Metter GE
J Clin Oncol; 1985 Mar; 3(3):385-92. PubMed ID: 3838343
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer. Chemotherapy.
Gibbons RP
Cancer; 1987 Aug; 60(3 Suppl):586-8. PubMed ID: 3297287
[TBL] [Abstract][Full Text] [Related]
26. Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.
Murphy GP; Priore RL; Scardino PT
Urology; 1988 Jul; 32(1):33-40. PubMed ID: 3291371
[TBL] [Abstract][Full Text] [Related]
27. Cause-specific actuarial survival analysis: a useful method for reporting survival data in men with clinically localized carcinoma of the prostate.
Lepor H; Kimball AW; Walsh PC
J Urol; 1989 Jan; 141(1):82-4. PubMed ID: 2908960
[TBL] [Abstract][Full Text] [Related]
28. [Response to chemotherapy in endocrine therapy-relapsed and -resistant prostate cancer].
Akimoto S; Akakura K; Masai M; Shimazaki J
Hinyokika Kiyo; 1991 Jan; 37(1):31-7. PubMed ID: 1707216
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
Laurie JA; Hahn RG; Therneau TM; Patel SR; Mailliard JA; Windschitl HE; Twito DI; Morton RF; Krook JE
Cancer; 1992 Mar; 69(6):1440-4. PubMed ID: 1540881
[TBL] [Abstract][Full Text] [Related]
30. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.
Seidman AD; Scher HI; Petrylak D; Dershaw DD; Curley T
J Urol; 1992 Mar; 147(3 Pt 2):931-4. PubMed ID: 1371564
[TBL] [Abstract][Full Text] [Related]
31. Comparison of various assay systems for prostate-specific antigen standardization.
Kuriyama M; Akimoto S; Akaza H; Arai Y; Usami M; Imai K; Tanaka Y; Yamazaki H; Kawada Y; Koiso K
Jpn J Clin Oncol; 1992 Dec; 22(6):393-9. PubMed ID: 1283993
[TBL] [Abstract][Full Text] [Related]
32. [Anti-androgen therapy of prostatic cancer and reactivation (author's transl)].
Ohtsuka K
Nihon Hinyokika Gakkai Zasshi; 1979 Nov; 70(11):1210-20. PubMed ID: 529649
[No Abstract] [Full Text] [Related]
33. Chemotherapy for endocrine-therapy-refractory prostate cancer.
Akimoto S; Ohki T; Akakura K; Masai M; Shimazaki J
Cancer Chemother Pharmacol; 1994; 35 Suppl():S18-22. PubMed ID: 7527733
[TBL] [Abstract][Full Text] [Related]
34. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
35. [Treatment for hormone-refractory or relapsing prostatic cancer].
Hirao Y; Ozono S; Okajima E
Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492
[TBL] [Abstract][Full Text] [Related]
36. [New combination chemotherapy in refractory rhabdomyosarcoma of the prostate: a case report and review of the literature].
Takeuchi T; Komeda H; Oguchi K; Ishihara S; Iwata H; Kanematsu M; Kuriyama M; Ban Y; Tanaka T
Hinyokika Kiyo; 1987 Nov; 33(11):1899-905. PubMed ID: 2451411
[TBL] [Abstract][Full Text] [Related]
37. Adult medulloblastoma: multiagent chemotherapy.
Greenberg HS; Chamberlain MC; Glantz MJ; Wang S
Neuro Oncol; 2001 Jan; 3(1):29-34. PubMed ID: 11305414
[TBL] [Abstract][Full Text] [Related]
38. [Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer].
Maki Y; Tsushima T; Nasu Y; Kumon H; Ohmori H; Tanahashi T; Nanba K; Ohashi T; Kondo K; Saika T; Asahi T; Saegusa M; Ozaki Y; Yamashita Y; Katayama Y; Kobuke M; Uno S; Ochi J; Kobashi K; Hata K
Nihon Hinyokika Gakkai Zasshi; 1998 Jul; 89(7):657-64. PubMed ID: 9739587
[TBL] [Abstract][Full Text] [Related]
39. European experience with ifosfamide in lymphomas.
von Kalle AK; Schaadt M; Diehl V
Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
[TBL] [Abstract][Full Text] [Related]
40. Etoposide in prostate cancer.
Kamradt JM; Pienta KJ
Expert Opin Pharmacother; 2000 Jan; 1(2):271-5. PubMed ID: 11249548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
